Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · May 1, 2018
Trial Information
Current as of July 07, 2025
Completed
Keywords
ClinConnect Summary
Opioid-induced constipation can lead to serious complications, including small bowel obstruction, fecal impaction, and bowel perforation. Not only are the medical complications potentially severe, patient quality of life can also be impacted. Two agents are currently available for opioid-induced constipation - oral and subcutaneous methylnaltrexone and oral naloxegol. Mechanistically, both agents antagonize the peripheral mu-opioid receptor in the gastrointestinal tract to decrease constipation without reversing the systemic analgesic effects of opiates. The literature currently available h...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Complaint of opioid-induced constipation refractory to other therapy (enemas, laxatives, stool softeners)
- • Age≥18y/o
- • Not pregnant or lactating (negative urinary pregnancy test)
- • No contraindication to Methylnaltrexone or Naloxegol
- Exclusion Criteria:
- • Age\<18y/o
- • Pregnancy or lactation
- • Contraindication to Methylnaltrexone or Naloxegol
- • Assigned NPO
- • Small bowel obstruction
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Patients applied
Trial Officials
KARA B GODDARD, PharmD, BCPS
Principal Investigator
UNIVERSITY OF MISSOURI HEALTH CARE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials